• Organizations: Aviceda Therapeutics
Aviceda raises $207M to support phase 3 testing of AVD-104 for GA
Business

Aviceda raises $207M to support phase 3 testing of AVD-104 for GA

Financing will support advancement of AVD-104, designed to target a specific area of the innate immune response relating to AMD.
Aviceda reports topline data from SIGLEC trial for GA
Pipeline

Aviceda reports topline data from SIGLEC trial for GA

Company reports AVD-104 demonstrating clinical and safety efficacy in part 1 of the phase 2/3 study.
Aviceda doses first patient with AVD-104 in phase 2 study for GA
Pipeline

Aviceda doses first patient with AVD-104 in phase 2 study for GA

SIGLEC trial is a two-part trial assessing AVD-104 as the first therapy to treat the underlying causes of AMD.
FDA clears Aviceda's IND application for GA candidate
Pipeline

FDA clears Aviceda's IND application for GA candidate

Acceptance clears the company to begin enrollment for a phase 2 trial on AVD-104.
Aviceda submits IND for AVD-104 to treat GA secondary to AMD
Pipeline

Aviceda submits IND for AVD-104 to treat GA secondary to AMD

The company also submitted a Fast Track Designation application, per the FDA’s request.